English

Year-end Report 2013

Report this content

Summary of the financial year January 1st– December 31st 2013

  • Net turnover amounted to SEK 0 (0)
  • Profit after financial items amounted to SEK -2 778 419 (-2 545 416)

    
Significant events during the financial year 2013

  • Raising of loans on a total of 3 500 000 , in addition to 3 650 000 SEK raised in connection with it during December 2012 through a rights issue completed
  • Patents have been approved in Japan
  • New patent application has been filed
  • Trademark registrations have been submitted
  • The company has hired Magnus Schnürer as CTO for the Company
  • The Company has appointed Henrik Norström as CFO of the Company
  • The Company has engaged IHE (Institute for Health Economics), Lund, Sweden, to implement a WTP (Willingness to Pay) study in order to highlight the added value, both quantitative and qualitative that Brighter One™ and Brighter Test Strips™ creates for the diabetic patient, the patient’s family and the caregiver. This study will form the basis of TLVs (Dental and Pharmaceutical Benefits Agency) resolution on remuneration for Brighter One™, and Brighter Test Strips™
  • Brighter participated in Medica, the world's largest medical technology and pharmaceutical trade fair in Düsseldorf, Germany
  • The company has signed a Letter of Intent with All Medicus Ltd. for the distribution of Brighter's products in South Korea , Indonesia, Thailand and Malaysia
  • The Company has entered into agreements for the exclusive license for the sale of future products as a result of the Eurostar program of micro needles
  • The Company has entered into a number of supplier agreements for the production of Brighter One™

   
Message from the CEO

It has been an eventful year that has passed and many things have happened. In the information memorandum (in Swedish only) published we elaborate further of what has happened during the year, so this year's message from the CEO is a little shorter than usual.

Personally I find the reception of Brighter One™ at Medica to be one of the year's main highlights, as it clearly confirms that what we are doing is absolutely right. During the third quarter the focus lied in great part in the more expansive pre-launch process and preparing for the move to NASDAQ OMX First North. It is rewarding to be able to offer all our shareholders to participate on equal terms in our effort forward.

Just like last year, I would like to end by sending a thank you to all our shareholders and although we are not always able, or allowed, to answer all your questions I ask you to continue sending us your tips, comments and recommendations.

Truls Sjöstedt
CEO Brighter AB (publ)

For further information, please contact:

Truls Sjöstedt, CEO
Telephone: +46 709 73 46 00
E-mail: truls.sjostedt@brightercompany.com

Henrik Norström, acting CFO
Telephone: +46 733 40 30 45
E-mail: henrik.norstrom@brightercompany.com

Gert Westergren, Chairman of the Board
Telephone: + 46 705 55 77 99
E-mail: gert.westergren@brightercompany.com

     
Om Brighter AB (publ)

Brighter One ™ – the patented all-in-one solution that combines the five things that millions of diabetics need to use several times every day to survive and feel well.

Brighter develops and commercializes innovative solutions for diabetes self-care. The Company's shares are listed on AktieTorget. More information is available at www.aktietorget.se.




Tags:

brighter

Documents & Links